Concepedia

Angel FowlerTaylor

AF

Statistics

Publications

11

Citations

3.1K

H-Index

11

Active since

2001

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Dartmouth College

National Jewish Health

University of Colorado Denver

Angel FowlerTaylor is an author at Novartis (United States) specializing in allergy, omalizumab therapy, and life sciences.

Publications per year

2001–2015

11

Publications

11

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

William W. Busse, Jonathan Corren, Bobby Q. Lanier et al. · Journal of Allergy and Clinical Immunology · 2001 · 1.3K citations · Full text

, , +16

Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma

Ratko Djukanović, Susan J. Wilson, Monica Kraft et al. · American Journal of Respiratory and Critical Care Medicine · 2004 · 648 citations

, , +16

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

Paul Chervinsky, Thomas B. Casale, Robert G. Townley et al. · Annals of Allergy Asthma & Immunology · 2003 · 213 citations

, , +14

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

William E. Berger, Niroo Gupta, Margaret McAlary et al. · Annals of Allergy Asthma & Immunology · 2003 · 183 citations

, , +16

Omalizumab is effective in the long-term control of severe allergic asthma

Bobby Q. Lanier, Jonathan Corren, William R. Lumry et al. · Annals of Allergy Asthma & Immunology · 2003 · 183 citations

, , +13

1–5 of 11